● Four-/five-plasmid transient transfection HEK293 cell systems, including Genevoyager’s optimized production platform
● Client-supplied cell lines

● High viral titers in harvest supernatant
● Processes readily scalable
● Animal component–free raw materials
● Cost-effective production

● Effective removal of impurities such as HCP and HCD
● Maximized viral infectivity
● Simple and robust operations
● Easily scalable in a linear manner
● Reduced overall cost

● Stirred-tank bioreactors (5 L, 10 L, 50 L, 200 L)

● Designed and operated in accordance with BSL-2 requirements
● Manufacturing suites designed and constructed in compliance with FDA, EMA, and NMPA GMP standards, featuring unidirectional flow and independent HVAC systems